Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287924 | 0.86 | HIF1A (0.74) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL10388545 | 0.86 | HIF1A (0.74) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL28906915 | 0.81 | HIF1A (0.64) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL2979268 | 0.80 | HIF1A (0.62) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL2987335 | 0.79 | HIF1A (0.61) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL2469342 | 0.78 | HIF1A (0.59) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL3050018 | 0.75 | ALDH1A1 (0.59) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL4820844 | 0.75 | HIF1A (0.72) | HIF1ATSHRGAAALDH1A1ALOX15 | |
| SCHEMBL3957261 | 0.75 | ATM (0.60) | HIF1ATSHRALDH1A1ALOX15MAPT | |
| SCHEMBL4614260 | 0.74 | HIF1A (0.52) | HIF1ATSHRGAAALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4665239-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| JP-2002512230-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1071668-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Du Pont Pharmaceuticals Company (US) | 2001-01-31 | — | — | EP | claimed |
| WO-1999054308-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-28 | — | — | WO | claimed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | HIF1A 2570/4885JAK2 1472/4885PTK2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.